Licensing status

Publication and contact information


Pancreatic cancer

G protein-coupled receptor 81 (GPR81)

Cell-based, patient sample and mouse studies suggest inhibiting the lactate receptor GPR81 could help treat pancreatic cancer. In a collection of 158 tumors from patients with pancreatic ductal adenocarcinomas (PDACs), GPR81 levels were elevated in 148 of the specimens. In human PDAC cell lines grown in lactate, but not glucose, GPR81 shRNA decreased mitochondrial activity by 50% and increased apoptosis by 500% compared with control shRNA. In a mouse xenograft model of PDAC, GPR81 shRNA decreased tumor growth and metastatic burden and increased survival compared with shRNA control. Next steps could include designing or screening for GPR81 inhibitors.

SciBX 7(28); doi:10.1038/scibx.2014.825
Published online July 24, 2014

Patent and licensing status unavailable

Roland, C.L. et al. Cancer Res.; published online June 13, 2014;
Contact: Craig D. Logsdon, The University of Texas MD Anderson Cancer Center, Houston, Texas